TD Cowen Raises its Price Target on Roivant Sciences (ROIV) [Yahoo! Finance]
Roivant Sciences Ltd. - Common Shares (ROIV)
Company Research
Source: Yahoo! Finance
On May 21, 2026, TD Cowen raised the firm's price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $41 from $38 and maintained a Buy rating on the shares. TD Cowen said IMVT-1402 toplined impressive Ph2b D2T RA data, with ACR20 of 73%, ACR50 of 55%, and ACR70 of 36%. The firm also said Roivant has many more catalysts ahead. Citi also raised the firm's price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $42 from $35 and maintained a Buy rating on the shares. Citi said it sees further upside from Roivant's second half of 2026 data catalysts and kept the stock as a top pick following the IMVT-1402 data. TD Cowen Raises its Price Target on Roivant Sciences (ROIV) A day earlier, Roivant Sciences Ltd. (NASDAQ:ROIV) reported fiscal Q4 EPS of 28c, compared to the consensus estimate of (35c). Revenue totaled $2.52M, versus the consensus estimate of $3.91M. CEO Matt Gline said the positive Period 1 data from the IMVT-1402 trial in D2T RA showed “exciting potential” for a new treatment
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Nomura Healthcare Fund Q1 2026 Commentary [Seeking Alpha]Seeking Alpha
- Baron Health Care Fund Q1 2026 Shareholder Letter [Seeking Alpha]Seeking Alpha
- Roivant Sciences (ROIV) had its "buy" rating reaffirmed by Guggenheim.MarketBeat
- Litigation Windfall Driving Roivant Sciences' Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV) [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences (ROIV) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d)" to "sell (d-)".MarketBeat
ROIV
Earnings
- 5/20/26 - Beat
ROIV
Sec Filings
- 5/22/26 - Form 4
- 5/22/26 - Form 4
- 5/22/26 - Form 144
- ROIV's page on the SEC website